Skip Ribbon Commands
Skip to main content
TitleUse SHIFT+ENTER to open the menu (new window).
  
Created ByUse SHIFT+ENTER to open the menu (new window).
  
PublishedUse SHIFT+ENTER to open the menu (new window).
  
Category
  
Edit
PostAuthorPicUse SHIFT+ENTER to open the menu (new window).
  
RelatedLinks1Use SHIFT+ENTER to open the menu (new window).
  
RelatedLinks2Use SHIFT+ENTER to open the menu (new window).
  
RelatedLinks3Use SHIFT+ENTER to open the menu (new window).
  
RelatedLinks4Use SHIFT+ENTER to open the menu (new window).
  
RelatedLinks5Use SHIFT+ENTER to open the menu (new window).
  
Books
MonthYearUse SHIFT+ENTER to open the menu (new window).
  
YearUse SHIFT+ENTER to open the menu (new window).
  
PostAuthorNameUse SHIFT+ENTER to open the menu (new window).
  
PostAuthorLinkUse SHIFT+ENTER to open the menu (new window).
  
# CommentsUse SHIFT+ENTER to open the menu (new window).
  
# Comments with Link
  
Approval StatusUse SHIFT+ENTER to open the menu (new window).
  
  
No presence informationBetsy Garman5/22/2012 9:20 AMInstrumentation/Technology Larry J. Kricka DPhil, FACB, CSci, CChem, FRSC, FRCPath
May 20122012Larry J. Kricka DPhil, FACB, CSci, CChem, FRSC, FRCPathLarry J. Kricka DPhil, FACB, CSci, CChem, FRSC, FRCPath0Approved
  
No presence informationBetsy Garman5/15/2012 9:10 AMRenal/GI/Hepatic Jack Zakowski, PhD, FACB

​References

1. Myers, et al, Clin Chem 2006:52, 5-18.
2. Greenberg, et al, Clin Chem 2011:58, 391-401.
3. Levey, et al, Clin Chem 2007:53, 766-772.
4. National Kidney Disease Education Program, Working Group meeting 2011. 

5. Levey, et al, Ann Intern Med 2009:150, 604-612.
6. National Kidney Disease Education Program: Laboratory Evaluation.

7. National Kidney Disease Education Program: CKD and Drug Dosing: Information for Providers.

8. Schwartz, et al, J Am Soc Nephrol 2009:20, 629-637.
9. Grubb, et al, Clin Chem Lab Med 2010:48, 1619-1621.

May 20122012Jack Zakowski, PhD, FACBJack Zakowski, PhD, FACB0Approved
  
No presence informationBetsy Garman5/8/2012 11:59 AMSpecial Populations Khosrow Adeli, PhD, FCACB, FACB, DABCC

​Caliper Project

Caliper Database

Colantonio DA, Kyriakopoulou L, Chan MK, et al: Closing the Gaps in Pediatric Laboratory Reference Intervals: A CALIPER Database of 40 Biochemical Markers in a Healthy and Multiethnic Population of Children. Clin Chem 2012 May;58(5):854-68.

May 20122012Khosrow Adeli, PhD, FCACB, FACB, DABCCKhosrow Adeli, PhD, FCACB, FACB, DABCC4Approved
  
No presence informationBetsy Garman5/1/2012 9:08 AMCVD/Markers/Risk Factors Andrew Hoofnagle, MD, PhD

​References

1. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117:746-56.
2. Hoofnagle AN, Wu M, Gosmanova AK, Becker JO, Wijsman EM, Brunzell JD, et al. Low Clusterin Levels in High-Density Lipoprotein Associate With Insulin Resistance, Obesity, and Dyslipoproteinemia. Arterioscler Thromb Vasc Biol. 2010;30:2528-34.
3. Green PS, Vaisar T, Pennathur S, Kulstad JJ, Moore AB, Marcovina S, et al. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation. 2008;118:1259-67.
4. Karlsson H, Leanderson P, Tagesson C, Lindahl M. Lipoproteomics I: Mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics. 2005;5:551-65.
5. Peterson MM, Mack JL, Hall PR, Alsup AA, Alexander SM, Sully EK, et al. Apolipoprotein B Is an innate barrier against invasive Staphylococcus aureus infection. Cell Host Microbe. 2008;4:555-66.

May 20122012Andrew Hoofnagle, MD, PhDAndrew Hoofnagle, MD, PhD2Approved
  
No presence informationAACC\bgarman4/24/2012 8:25 AMCase Study William E. Winter, MD, and Roger L. Bertholf, PhD
April 20122012William E. Winter, MD, and Roger L. Bertholf, PhDWilliam E. Winter, MD, and Roger L. Bertholf, PhD6Approved
  
No presence informationAACC\bgarman4/17/2012 8:29 AMInstrumentation/Technology; Cancer and Tumor Markers; Diabetes/Endocrinology Alicia Algeciras-Schimnich, PhD

​References

1. Algeciras-Schimnich A, Lasho MA, Ness KM, Cheryk LA, Grebe SK. Thyroid 2011; 21(7):813-4.
2. Spencer C, Petrovic I, Fatemi S. J Clin Endocrinol Metab. 2011 May;96(5):1283-91.
3. Hoofnagle AN, Becker JO, Wener MH, Heinecke JW.  Clin Chem. 2008;54(11):1796-804.

 

April 20122012Alicia Algeciras-Schimnich, PhDAlicia Algeciras-Schimnich, PhD0Approved
  
No presence informationAACC\bgarman4/10/2012 8:28 AMNutrition Kenneth Hoekstra, PhD, HCLD, FACB
April 20122012Kenneth Hoekstra, PhD, HCLD, FACBKenneth Hoekstra, PhD, HCLD, FACB1Approved
  
No presence informationAACC\bgarman4/3/2012 8:31 AMDiabetes/Endocrinology William E. Winter, MD
April 20122012William E. Winter, MDWilliam E. Winter, MD0Approved
  
No presence informationAACC\bgarman3/27/2012 9:34 AM Christopher McCudden, PhD, DABCC, FACB
March 20122012Christopher McCudden, PhD, DABCC, FACBChristopher McCudden, PhD, DABCC, FACB0Approved
  
No presence informationAACC\bgarman3/20/2012 9:21 AMTDM/Toxicology Roger L. Bertholf, PhD, and William E. Winter, MD

​References

 1. Baselt, RC. Disposition of Toxic Drugs and Chemicals in Man. Seventh Edition. 2004. Biomedical Publications, Foster City, CA.

 

 

 

 

March 20122012Roger L. Bertholf, PhD, and William E. Winter, MDRoger L. Bertholf, PhD, and William E. Winter, MD0Approved
  
No presence informationAACC\bgarman3/13/2012 8:22 AMManagement/Medical Informatics Darci Block, PhD, DABCC

​References:
1. Wians, FH.  To test or not to test? Opening Pandora’s Box.  Lab Medicine. 2004; 35:707.
2. Ritchie, JC.  NACBlog Is it Time to Remove the Stigma of LDT from Body Fluid Chemistry Assays? July 26, 2011
3. Clinical and Laboratory Standards Institute: Analysis of Body Fluids in Clinical Chemistry; Approved Guideline. Clinical and Laboratory Standards Institute, Wayne, PA, 2007, CLSI document C49-A (ISBN 1-56238-638-7) 
4. Chemistry and Toxicology CAP checklist. 2011

March 20122012Darci Block, PhD, DABCCDarci Block, PhD, DABCC0Approved
  
No presence informationAACC\bgarman3/6/2012 8:29 AMInstrumentation/Technology Frederick G. Strathmann, PhD, DABCC

​References:

1. Chace D, Mass spectrometry in the clinical laboratory. Chemical reviews, 2001. 101(2): p. 445-772.

2. Strathmann FG and Hoofnagle AN, Current and future applications of mass spectrometry to the clinical laboratory. Am J Clin Pathol, 2011. 136(4): p. 609-16.

Conference
September 6-7, 2012
Chicago, IL
 

 

 

March 20122012Frederick G. Strathmann, PhD, DABCCFrederick G. Strathmann, PhD, DABCC5Approved
  
No presence informationAACC\bgarman2/28/2012 8:28 AMInstrumentation/Technology; Molecular Pathology and Genetics Linnea M. Baudhuin, PhD, DABMG

​References:

1. Epstein RS, Moyer TP, Aubert RE,  et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). Journal of the American College of Cardiology 2010;55:2804-12.
2. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proceedings of the National Academy of Sciences of the United States of America 2004;101:4180-5.
3. Nissen SE. Pharmacogenomics and clopidogrel: irrational exuberance? JAMA 2011;306:2727-8.
4. Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011;306:2704-14.
5. Topol EJ, Teirstein PS, Price M, et al. 2011.

NACB Laboratory Medicine Practice Guideline on Pharmacogenomics
NACB Laboratory Medicine Practice Guideline on Pharmacogenetics



February 20122012Linnea M. Baudhuin, PhD, DABMGLinnea M. Baudhuin, PhD, DABMG0Approved
  
No presence informationAACC\bgarman2/21/2012 8:44 AMTDM/Toxicology Uttam Garg, PhD, DABCC, DABFT, FACB

​References:

  1. Garg U, Ferguson AM. Alternate specimens for drugs-of-abuse testing: preanalytical and interpretative considerations. In Clinical Toxicology Testing: A Guide for laboratory Professionals 2012. Eds M Barbarajean, MG Bissell, TC Kwong, AHB Wu, CAP Press, pp 71-80.
    2.  
  2. Lo Muzio L, Falaschini S, Rappelli G,  et al. Saliva as a diagnostic matrix for drug abuse. Int J Immunopathol Pharmacol 2005;18:567-73.
    3.  
  3. Gambelunghe C, Rossi R, Ferranti C, Bacci M. Hair analysis by GC/MS/MS to verify abuse of drugs. J Appl Toxicol 2005;25:205-11.
    4.  
  4. Dolan K, Rouen D, Kimber J. An overview of the use of urine, hair, sweat and saliva to detect drug use. Drug Alcohol Rev 2004;23:213-7.

    5.  
     

     

     

     

     

     

     

     

     

     

     

     

     

February 20122012Uttam Garg, PhD, DABCC, DABFT, FACBUttam Garg, PhD, DABCC, DABFT, FACB1Approved
  
No presence informationAACC\bgarman2/14/2012 8:25 AMInstrumentation/Technology; Special Populations Donald H. Chace, PhD, MSFS, FACB
February 20122012Donald H. Chace, PhD, MSFS, FACBDonald H. Chace, PhD, MSFS, FACB14Approved
  
No presence informationAACC\bgarman2/7/2012 8:51 AMManagement/Medical Informatics; Government Affairs/Patient Safety Gregory J. Buffone, PhD
February 20122012Gregory J. Buffone, PhDGregory J. Buffone, PhD1Approved
  
No presence informationAACC\bgarman1/31/2012 8:28 AMInstrumentation/Technology; POC Testing Douglas F. Stickle, PhD, DABCC, FACB

References

1. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol. 2005;27:81-90.

2. Hartert H. [Thrombelastography, a method for physical analysis of blood coagulation.] Z Gesamte Exp Med 1951;117:189-203.

3. Kitchen DP, Kitchen S, Jennings I, Woods T, Walker I. Quality assurance and quality control of thromboelastography and rotational thromboelastometry: the UK NEQAS for blood coagulation experience. Semin Thromb Hemost 2010;36:757-63.

4. Chitlur M, Lusher J. Standardization of thromboelastography: values and challenges. Semin Thromb Hemost 2010;36:701-11.

​

 

January 20122012Douglas F. Stickle, PhD, DABCC, FACBDouglas F. Stickle, PhD, DABCC, FACB5Approved
  
No presence informationAACC\bgarman1/24/2012 8:28 AMMolecular Pathology and Genetics Patti Jones, PhD, and Jason Y. Park, MD

2012 AACC/AMP Molecular Pathology Course

​

January 20122012Patti Jones, PhD, and Jason Y. Park, MD Patti Jones, PhD, and Jason Y. Park, MD2Approved
  
No presence informationAACC\bgarman1/17/2012 10:12 AMCase Study William E. Winter, MD, and Roger Bertholf, PhD

​References

[1] Luten M, Roerdinkholder-Stoelwinder B, Bost HJ, Bosman GJ.
Survival of the fittest?--survival of stored red blood cells after transfusion. Cell Mol Biol (Noisy-le-grand). 2004 Mar;50(2):197-203.
[2] Spencer DH, Grossman BJ, Scott MG. Red cell transfusion decreases hemoglobin A1c in patients with diabetes. Clin Chem. 2011 Feb;57(2):344-6.

 

January 20122012William E. Winter, MD, and Roger Bertholf, PhDWilliam E. Winter, MD, and Roger Bertholf, PhD3Approved
  
No presence informationAACC\bgarman1/10/2012 9:36 AMCVD/Markers/Risk Factors William E. Winter, MD

References

1. Greenland P, Knoll MD, Stamler J, et al. Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events. JAMA. 2003;290:891-7.

2. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ.Prevalence of Conventional Risk Factors in Patients With Coronary Heart Disease. JAMA. 2003;290:898-904.
 

 

 

 

 

​

 

January 20122012William E. Winter, MDWilliam E. Winter, MD2Approved
  
No presence informationAACC\bgarman1/3/2012 9:00 AMDiabetes/Endocrinology Julie Rosser, DO, and Ronald Whitley, PhD
January 20122012Julie Rosser, DO, and Ronald Whitley, PhDJulie Rosser, DO, and Ronald Whitley, PhD0Approved
  
No presence informationAACC\bgarman12/29/2011 8:20 AM Patricia Jones, PhD, DABCC, FACB
December 20112011Patricia Jones, PhD, DABCC, FACBPatricia Jones, PhD, DABCC, FACB1Approved
  
No presence informationAACC\bgarman12/20/2011 8:26 AMCase Study William E. Winter, MD, DABCC, FACB

Reference

1. Ermensa AAM, Vlasveldb LT, Lindemansc J. Significance of elevated cobalamin (vitamin B12) levels in blood. Clinical Biochemistry 36 (2003) 585–590

​

December 20112011William E. Winter, MD, DABCC, FACBWilliam E. Winter, MD, DABCC, FACB0Approved
  
No presence informationAACC\bgarman12/13/2011 9:22 AMDiabetes/Endocrinology; Case Study William E. Winter, MD, and Patti Jones, PhD

​1. Velloso LA, Kämpe O, Hallberg A, Christmanson L, Betsholtz C, Karlsson FA. Demonstration of GAD-65 as the main immunogenic isoform of glutamate decarboxylase in type 1 diabetes and determination of autoantibodies using a radioligand produced by eukaryotic expression. J Clin Invest. 1993 May;91(5):2084-90.

2. Scherbaum WA, Trischler G, Pfeiffer EF. Non-human primate pancreas as a substrate for the detection of islet-cell antibodies in human sera. Diabetes Res Clin Pract. 1989 Jun 20;7(1):1-5.

3. Bergerot I, Souchier C, Thivolet C. Heterogeneity of islet cell cytoplasmic antibodies and autoantibodies to glutamate decarboxylase in relatives of patients with type 1 (insulin-dependent) diabetes. C R Acad Sci III. 1993 Nov;316(11):1368-73.

4. 4. Colman PG, Nayak RC, Campbell IL, Eisenbarth GS. Binding of cytoplasmic islet cell antibodies is blocked by human pancreatic glycolipid extracts  Diabetes. 1988 May;37(5):645-52.

5. Winter WE, Schatz DA. Autoimmune markers in diabetes. Clin Chem. 2011 Feb;57(2):168-75.

December 20112011William E. Winter, MD, and Patti Jones, PhDWilliam E. Winter, MD, and Patti Jones, PhD0Approved
  
No presence informationAACC\bgarman12/6/2011 9:22 AMCase Study William E. Winter, MD, DABCC, FACB

Additional Contributors to this blog post:


Neil S. Harris, MD, Associate Professor of Pathology



Lindsay Bazydlo, PhD, Assistant Professor Pathology

 

 

 

 

 

 

​

 

December 20112011William E. Winter, MD, DABCC, FACBWilliam E. Winter, MD, DABCC, FACB3Approved
  
No presence informationAACC\bgarman11/29/2011 8:42 AMGovernment Affairs/Patient Safety James Faix, MD
November 20112011James Faix, MDJames Faix, MD0Approved
  
No presence informationAACC\bgarman11/22/2011 6:57 AMCancer and Tumor Markers D. Robert Dufour, MD, FACB

References
1. Johansson J-E, Andrén O, Andersson S-O, Dickman PW, Holmberg L, Magnuson A, et al. Natural History of Early, Localized Prostate Cancer. JAMA: The Journal of the American Medical Association 2004;291:2713-2719.
2. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Mortality Results from a Randomized Prostate-Cancer Screening Trial. New England Journal of Medicine 2009;360:1310-1319.
3. Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Screening and Prostate-Cancer Mortality in a Randomized European Study. New England Journal of Medicine 2009;360:1320-1328.
4. Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, et al. Radical Prostatectomy Versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized Trial. Journal of the National Cancer Institute 2008;100:1144-1154. 


 
 

 

 

 

 

 

 

​

 

November 20112011D. Robert Dufour, MD, FACBD. Robert Dufour, MD, FACB3Approved
  
No presence informationAACC\bgarman11/15/2011 9:16 AMDiabetes/Endocrinology; Instrumentation/Technology Steven Soldin, PhD, DABCC, FACB
November 20112011Steven Soldin, PhD, DABCC, FACBSteven Soldin, PhD, DABCC, FACB2Approved
  
No presence informationAACC\bgarman11/8/2011 8:35 AMDiabetes/Endocrinology; POC Testing David G. Grenache, PhD, DABCC, FACB

References

1. NACB. Evidenced-based Practice for Point-of-Care Testing. NACB Practice Guidelines. 2006.

2. When the test really counts. Consumer Reports 2003 February: 45-50.

3. Cervinski MA, Lockwood CM, Ferguson AM, Odem RR, Stenman UH, Alfthan H, et al. Qualitative point-of-care and over-the-counter urine hCG devices differentially detect the hCG variants of early pregnancy. Clin Chim Acta. 2009;406(1-2):81–85.

4. Sigel CS, Grenache DG. Detection of unexpected isoforms of human chorionic gonadotropin by qualitative tests. Clin Chem. 2007;53(5):989–990.

5. Gronowski AM, Cervinski M, Stenman U-H, Woodworth A, Ashby L, Scott MG. False-negative results in point-of-care qualitative human chorionic gonadotropin (hCG) devices due to excess hCGbeta core fragment. Clin Chem. 2009;55(7):1389–1394.

6. Greene, D: What could be simpler than a pregnancy test? NACBLOG

 

 

 

 

 

 

 ​

 

November 20112011David G. Grenache, PhD, DABCC, FACBDavid G. Grenache, PhD, DABCC, FACB0Approved
  
No presence informationAACC\bgarman11/1/2011 8:26 AMCase Study; Diabetes/Endocrinology William E. Winter, MD, DABCC, FACB
November 20112011William E. Winter, MD, DABCC, FACBWilliam E. Winter, MD, DABCC, FACB21Approved
  
No presence informationAACC\bgarman10/25/2011 8:15 AMGovernment Affairs/Patient Safety Patricia M. Jones, PhD, DABCC, FACB

Laboratory-Developed Tests Online Course​

October 20112011Patricia M. Jones, PhD, DABCC, FACBPatricia M. Jones, PhD, DABCC, FACB1Approved
  
No presence informationAACC\bgarman10/18/2011 8:19 AMCancer and Tumor Markers Joshua Bornhorst, PhD

References

1. Kyle RA, Rajkumar SV “Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.” Leukemia. (2009); 23(1):3-9.
2. Fonesca et. al. “International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.” Leukemia. (2009); 23(12):2210-21.
3. Keren, D.F. “Heavy/Light-chain analysis of monoclonal gammopathies. Clin Chem, (2009); 55, 1606-1608.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

​

 

October 20112011Joshua Bornhorst, PhDJoshua Bornhorst, PhD1Approved
  
No presence informationAACC\bgarman10/11/2011 8:05 AMMolecular Pathology and Genetics K.T. Jerry Yeo, PhD

References

1) Neumann PJ, Cohen JT, Hammitt JK, et al.  Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ. 2010 Dec 28. DOI: 10.1002/hec.1704
2) Direct-To-Consumer Genetic Tests: Misleading Test Results Are Further Complicated by Deceptive Marketing and Other Questionable Practices GAO-10-847T, Jul 22, 2010
​

October 20112011K.T. Jerry Yeo, PhDK.T. Jerry Yeo, PhD3Approved
  
No presence informationAACC\bgarman10/4/2011 8:48 AMTDM/Toxicology Donald L. Frederick, PhD, DABFT

Clinical and Forensic Toxicology News September 2011​

October 20112011Donald L. Frederick, PhD, DABFTDonald L. Frederick, PhD, DABFT2Approved
  
No presence informationAACC\bgarman9/27/2011 8:37 AMManagement/Medical Informatics Joely Straseski, PhD

 

  1. Fraser CG. Biological Variation: From Principles to Practice. ASCP Press (2001).
    2.  
  2. Strathmann FG, Baird GS, Hoffman NG. Simulations of delta check rule performance to detect specimen mislabeling using historical laboratory data. Clin Chim Acta 412:1973-7 (2011).
 
​

 

September 20112011Joely Straseski, PhDJoely Straseski, PhD1Approved
  
No presence informationAACC\bgarman9/20/2011 7:58 AMCase Study; Special Populations; Molecular Pathology and Genetics William Winter, MD

(1) Schroeder V, Durrer D, Meili E, Schubiger G, Kohler HP. Congenital factor XIII deficiency in Switzerland: from the worldwide first case in 1960 to its molecular characterization in 2005. Swiss Med Wkly. 2007 May 19;137(19-20):272-8.
(2) Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia. 2008 Nov;14(6):1190-200.
(3) Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII Deficiency. Semin Thromb Hemost. 2009 Jun;35(4):426-38.
​

September 20112011William Winter, MDWilliam Winter, MD1Approved
  
No presence informationAACC\bgarman9/13/2011 9:10 AMDiabetes/Endocrinology Dina Greene, PhD

1. Gronowski AM, Cervinski M, Stenman UH, et al. False-negative results in point-of-care qualitative human chorionic gonadotropin (hCG) devices due to excess hCGbeta core fragment. Clinical Chemistry 2009:55;1389–1394.

2. Grenache DG, Greene DN, Dighe AS, et al. Falsely decreased human chorionic gonadotropin (hCG) results due to increased concentrations of the free beta subunit and the beta core fragment in quantitative hCG assays. Clinical Chemistry 2010:56;1839–1844.

​

September 20112011Dina Greene, PhDDina Greene, PhD1Approved
  
No presence informationAACC\bgarman9/7/2011 8:12 AMCase Study; Diabetes/Endocrinology William Winter, MD
September 20112011William Winter, MDWilliam Winter, MD10Approved
  
No presence informationAACC\bgarman8/30/2011 8:19 AMDiabetes/Endocrinology Douglas Stickle, PhD

References

1. American Diabetes Association. Standards of Medical Care in Diabetes—2011.
Diabetes Care 2011; 34, Supplement 1: S11-S61.

2. Sacks DB et al. Position Statement Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Diabetes Care 2011;34:1419-1423.

3. American College of Obstetricians and Gynecologists. Gestational Diabetes. ACOG Practice Bulletin Clinical Guidelines for Obstetrician-Gynecologists. Number 30, September 2001.

4. Coustan DR et al. Should the fifty-gram, one-hour plasma glucose screening test for gestational diabetes be administered in the fasting or fed state? Am J Obstet Gynecol 1986 May;154(5):1031-5.

5. Lewis GF et al. Prior feeding alters the response to the 50-g glucose challenge test in pregnancy. The Staub-Traugott effect revisited. Diabetes Care. 1993 Dec;16(12):1551-6.

6. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. World Health Organization, Dept Noncommunicable Disease Surveillance, Geneva, 1999.

​

 

August 20112011Douglas Stickle, PhDDouglas Stickle, PhD6Approved
  
No presence informationAACC\bgarman8/23/2011 8:06 AMCancer and Tumor Markers Callum Fraser, PhD

References
1.  Fraser CG. Fecal occult blood tests. Life savers or outdated colorectal screening tools? Clin Lab News 2011:37(3):8-10. swww.aacc.org/publications/cln/2011/march/Pages/FecalOccult.aspx
2.  AACC Lecture Library. Colon cancer: The role of fecal tests – 2011. 

3.  Fraser CG. Screening for colorectal neoplasia with faecal tests, Lancet Oncol 2011;12:516-7.
4.  Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007;146:244–55.
5.  Fraser CG, Mathew CM, McKay K, Carey FA, Steele RJ.  Automated immunochemical quantitation of haemoglobin in faeces collected on cards for screening for colorectal cancer. Gut 2008;57:1256-60.
6.  Brenner H, Haug U, Hundt S.  Sex differences in performance of fecal occult blood testing.  Am J Gastroenterol 2010;105:2457-64.
7.  Khalid-de Bakker CA, Jonkers DM, Sanduleanu S, et al. Test performance of fecal occult blood testing and sigmoidoscopy compared with colonoscopy screening for colorectal advanced adenoma. Cancer Prev Res 2011 Jul 12. Epub ahead of print
8.  Chen L-S, Yen A M-F, Chiu S H-Y, Liao C-S, Chen H-H. Baseline immunochemical faecal occult blood test (iFOBT) concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet Oncol 2011;12:551-8.
​

August 20112011Callum Fraser, PhDCallum Fraser, PhD0Approved
  
No presence informationAACC\bgarman8/16/2011 8:06 AMTDM/Toxicology Gwen McMillin, PhD
August 20112011Gwen McMillin, PhDGwen McMillin, PhD0Approved
  
No presence informationAACC\bgarman8/9/2011 9:24 AMSpecial Populations Douglas F. Stickle, PhD

References

1. Chemical & Engineering News, 17 January 2011, pp. 13-17
2. Bioanalysis 2010;2(8):1343-4.
3. Bioanalysis 2010;2(11):1781.
4. Mei JV, Alexander JR, Adam BW, Hannon WH. Use of filter paper for the collection and analysis of human whole blood specimens. J Nutr 2001;131(5):1631S-6S.
5. Egier DA, Keys JL, Hall SK, McQueen MJ. Measurement of hemoglobin A1c from filter papers for population-based studies. Clin Chem 2011;57(4):577-85.
6. Deniff P, Spooner S. The effect of hematocrit on assay bias when using dried blood spots samples for the quantitative bioanalysis of drugs. European Bioanlysis Forum Workshop: Connecting Strategies on Dried Blood Spots, June 17-18, 2010, Brussels, Belgium

7. Meany DL, Clarke W. Opiate DAU screening using dried urine specimens. Clin Chim Acta. 2009;401(1-2):188-9.

 

 

 

 

​

 

August 20112011Douglas F. Stickle, PhDDouglas F. Stickle, PhD2Approved
  
No presence informationAACC\bgarman8/2/2011 9:11 AMCase Study; Diabetes/Endocrinology William Winter, MD
August 20112011William Winter, MDWilliam Winter, MD9Approved
  
No presence informationAACC\bgarman7/26/2011 7:50 AMGovernment Affairs/Patient Safety James C. Ritchie, PhD

References
1. Clinical and Laboratory Standards Institute. Body Fluid Analysis for Cellular Composition; Approved Guideline. CLSI document H56-A [ISBN 1-56238-614-X]. Clinical and Laboratory Standards Institute, Wayne, PA, 2006
2. Clinical and Laboratory Standards Institute. Analysis of Body Fluids in Clinical Chemistry; Approved Guideline. CLSI document C49-A [ISBN 1-56238-638-7]. Clinical and Laboratory Standards Institute, Wayne, PA, 2007
3. Nontraditional Body Fluid Analysis, Sanford, KW, (2006)
 

​

July 20112011James C. Ritchie, PhDJames C. Ritchie, PhD1Approved
  
No presence informationAACC\bgarman7/19/2011 8:16 AMGovernment Affairs/Patient Safety Patti Jones, PhD, FACB, and Jason Park, MD

Comments Due by End of August 2011: Commercially Distributed In Vitro Diagnostic Products Labeled for Research use Only or Investigational Use Only.  Draft Guidance for Industry and FDA Staff​

July 20112011Patti Jones, PhD, FACB, and Jason Park, MDPatti Jones, PhD, FACB, and Jason Park, MD3Approved
  
No presence informationAACC\bgarman7/12/2011 8:05 AMDiabetes/Endocrinology William Winter, MD

* Wherrett DK, Bundy B, Becker DJ, et al: Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet [Epub June 27, 2011]

Orban T, Bundy B, Becker DJ, et al: Co-Stimulation Modulation with Abatacept in Patients with Recent-Onset Type 1 Diabetes: A Randomized Double-Masked Controlled Trial. Lancet [Epub June 28, 2011]

 

 

​

 

July 20112011William Winter, MDWilliam Winter, MD0Approved
  
No presence informationAACC\bgarman7/5/2011 8:32 AMCase Study William Winter, MD

Malone, B: Rethinking Ionized Calcium Test Utilization. Clinical Lab Strategies, May 2009​

July 20112011William Winter, MDWilliam Winter, MD13Approved
  
No presence informationAACC\bgarman6/28/2011 8:24 AMRenal/GI/Hepatic; TDM/Toxicology Angela M. Ferguson, PhD

References

1.  Myers GL, Miller WG, Coresh J et al. Recommendations for improving serum creatinine measurements: A report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006;52:5-18.
 
2.  National Kidney Disease Education Program: http://nkdep.nih.gov 
 

3.  Stevens LA, Nolin TD, Richardson MM, Feldman HI, Lewis JB, Rodby R, et al.  Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations.  Am J Kidney Dis 2009;54:33-42.

Additional Reading

 

Narva AS.  Assessment of Kidney Function for Drug Dosing.  Clin Chem 2009;55:1069-1611.
 
Fraser, Callum.  Estimating GFR: What’s Wrong with Using Serum Creatinine Alone? NACBLOG January 25, 2011.

 

​
Creatinine Calibration: An Inconvenient Truth
Josef Coresh, MD, PhD
AACC Annual Meeting Plenary Session
July 27, 2011 Georgia World Congress Center

 

June 20112011Angela M. Ferguson, PhDAngela M. Ferguson, PhD0Approved
  
No presence informationAACC\bgarman6/21/2011 8:40 AMManagement/Medical Informatics Roland Valdes, Jr, PhD


NACB Pharmacogenomics LMPG


Pharmacogenetics to Pharmacogenomics

Richard Weinshilboum, MD
AACC Annual Meeting Plenary Session
July 28, 2011 Georgia World Congress Center​

June 20112011Roland Valdes, Jr, PhDRoland Valdes, Jr, PhD0Approved
  
No presence informationAACC\bgarman6/14/2011 8:32 AMTDM/Toxicology Roger L. Bertholf, PhD

Additional Reading

Couto JE, Webster L, Romney MC, Leider HL, Linden A. Use of an algorithm applied to urine drug screening to assess adherence to an OxyContin regimen. Journal of Opioid Management 2009;5(6):359-64.


Reisfield GM, Goldberger BA, Crews BO, Pesce AJ, Wilson GR, Teitelbaum SA, Bertholf RL. Ethyl glucuronide, ethyl sufate, and ethanol in urine after sustained exposure to an ethanol-based hand sanitizer. Journal of Analytical Toxicology 2011;35(2):85-91.

Reisfield GM, Salazar E, Bertholf RL. Rational use and interpretation of urine drug testing in chronic opioid therapy. Annals of Clinical and Laboratory Science 2007;37(4):301-14.

Reisfield GM, Goldberger BA, Bertholf RL. “False positive” and “false negative” test results in clinical urine drug testing. Bioanalysis 2009;1(5):937-52.
​

June 20112011Roger L. Bertholf, PhDRoger L. Bertholf, PhD2Approved
  
No presence informationAACC\bgarman6/7/2011 8:28 AMCase Study William Winter, MD
June 20112011William Winter, MDWilliam Winter, MD0Approved
  
No presence informationAACC\bgarman5/31/2011 8:46 AMDiabetes/Endocrinology Ravinder Singh, PhD
 
 

​

May 20112011Ravinder Singh, PhDRavinder Singh, PhD2Approved
  
No presence informationAACC\bgarman5/24/2011 8:38 AMInstrumentation/Technology; Management/Medical Informatics Douglas F. Stickle, PhD
References
 

1. Demner-Fushman D, Chapman WW, McDonald CJ. What can natural language processing do for clinical decision support? J Biomed Inform 2009 Oct;42(5):760-72. Epub 2009 Aug 13. (Review)

2. IBM Watson

3. "Dr Watson, We Presume." Science 2011;331:992.

4. Main C, Moxham T, Wyatt JC, Kay J, Anderson R, Stein K. Computerized decision support systems in order communication for diagnostic, screening or monitoring test ordering: systematic reviews of the effects and cost-effectiveness of systems. Health Technol Assess 2010 Oct;14(48):1-227. (Review)

5. Robertson J, Walkom E, Pearson SA, Hains I, Williamsone M, Newby D. The impact of pharmacy computerised clinical decision support on prescribing, clinical and patient outcomes: a systematic review of the literature. Int J Pharm Pract 2010 Apr;18(2):69-87. (Review)

6. Hemmerling TM. Automated anesthesia. Curr Opin Anaesthesiol 2009 Dec;22(6):757-63. (Review)

7. Stivaros SM, Gledson A, Nenadic G, Zeng XJ, Keane J, Jackson A. Decision support systems for clinical radiological practice -- towards the next generation. Br J Radiol 2010 Nov;83(995):904-14. (Review)

8. Elkin PL, Liebow M, Bauer BA, Chaliki S, Wahner-Roedler D, Bundrick J, Lee M, Brown SH, Froehling D, Bailey K, Famiglietti K, Kim R, Hoffer E, Feldman M, Barnett GO. The introduction of a diagnostic decision support system (DXplain™) into the workflow of a teaching hospital service can decrease the cost of service for diagnostically challenging Diagnostic Related Groups (DRGs). Int J Med Inform 2010 Nov;79(11):772-7. Epub 2010 Oct 14. (Review)

9. "Schooling the Jeopardy! Champ: Far from Elementary." Science 2011;331:999.

10. Baker S. Final Jeopardy: Man vs. Machine and the Quest to Know Everything. Houghton Mifflin Harcourt Publishing, New York, 2011.

May 20112011Douglas F. Stickle, PhDDouglas F. Stickle, PhD1Approved
  
No presence informationAACC\bgarman5/17/2011 8:35 AMDiabetes/Endocrinology Martin Kroll, MD, FACB

References

1. Demers LM, Spencer CA. Laboratory support for the diagnosis and monitoring of thyoid disease. Laboratory Medicine Practice Guidelines. NACB vol. 13, 2002.

2. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease. Scientific review and guidelines for diagnosis and management. JAMA 2004;291:228-238.

3. Mariotti S. Solving the dilemma: what to do as a simple clinician. Endocrine Abstracts 2010;22:S13.4.

May 20112011Martin Kroll, MD, FACBMartin Kroll, MD, FACB2Approved
  
No presence informationAACC\bgarman5/10/2011 8:15 AMDiabetes/Endocrinology; POC Testing Brad Karon, MD, PhD

References

1. International Organization for Standardization. In vitro diagnostic test systems-Requirements for blood glucose monitoring systems for self-testing in managing Diabetes Mellitus. Report Number ISO 15197 2003.

2. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-67.3. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-61.

4. NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-97.

5. Karon BS, Boyd JC, Klee GG. Glucose meter performance criteria for tight glycemic control estimated by simulation modeling. Clin Chem 2010;56:1091-7.

May 20112011Brad Karon, MD, PhDBrad Karon, MD, PhD5Approved
  
No presence informationAACC\bgarman4/28/2011 3:21 PMDiabetes/Endocrinology; Case Study William Winter, MD
Additional Resources
 
HbA1c: An Overview of Current Analytical Testing Issues. CLN February 2011

ADA Endorses HbA1c for Diabetes Diagnosis. CLN February 2010

Expert Committee Endorses HbA1c Test for Diagnosing Diabetes. CLN August 2009

April 20112011William Winter, MDWilliam Winter, MD39Approved
  
No presence informationAACC\bgarman4/26/2011 9:03 AMInstrumentation/Technology Michael Bennett, PhDMass Spec in Clinical Labs. CLN September 2010
April 20112011Michael Bennett, PhDMichael Bennett, PhD4Approved
  
No presence informationAACC\bgarman4/19/2011 8:09 AMManagement/Medical Informatics; Instrumentation/Technology Fritz F. Parl, MD, PhD
April 20112011Fritz F. Parl, MD, PhDFritz F. Parl, MD, PhD1Approved
  
No presence informationAACC\bgarman4/12/2011 8:04 AMInstrumentation/Technology W. Greg Miller, PhD, and Gary L. Myers, PhD
References

1. ISO 17511:2003 In vitro diagnostic medical devices -Measurement of quantities in biological samples - Metrological traceability of values assigned to calibrators and control materials, International Organization for Standardization, Geneva, Switzerland, 2003.

2. Vesper HW, Thienpont LM. Traceability in laboratory medicine. Clin Chem 2009;55:1067-1075.

3. Miller WG, Myers GL, Rej R. Why commutability matters. Clin Chem 2006;52:553-4.

4. Vesper HW, Miller WG, Myers GL. Reference materials and commutability. Clin Biochem Rev 2007;28:139-47.

5. Clinical and Laboratory News, December 2010.

6. European Federation of Clinical Chemistry and Laboratory Medicine Newsletter January 2011.

 
April 20112011W. Greg Miller, PhD, and Gary L. Myers, PhDW. Greg Miller, PhD, and Gary L. Myers, PhD7Approved
  
No presence informationAACC\bgarman4/5/2011 8:02 AMDiabetes/Endocrinology; Case Study William Winter, MD, DABCC, FACBRodriguez, M. Big penalties for unconventional practice. Florida Medical Business, 2009; 9: 6.
April 20112011William Winter, MD, DABCC, FACBWilliam Winter, MD, DABCC, FACB11Approved
  
No presence informationAACC\bgarman3/29/2011 8:01 AMNew/Other Disease Markers ; Immunology/Infectious Disease  Alison Woodworth, PhD, DABCC, FACB

References

 

1. Russell JA. Management of sepsis. N Engl J Med. 2006 Oct 19;355(16):1699-713.

2. McGee KA. Procalcitonin: Clinical Utility in Diagnosing Sepsis. Clinical Laboratory News. 2009;35(7).

3. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14(1):R15.

4. Jones AE, Fiechtl JF, Brown MD, Ballew JJ, Kline JA. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Annals of emergency medicine. 2007 Jul;50(1):34-41.

5. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis. 2007 Mar;7(3):210-7.

6. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006 Jul;34(7):1996-2003.

7. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010 Feb 6;375(9713):463-74.

 

March 20112011Alison Woodworth, PhD, DABCC, FACB Alison Woodworth, PhD, DABCC, FACB6Approved
  
No presence informationAACC\bgarman3/22/2011 8:08 AMRenal/GI/Hepatic; POC Testing James H. Nichols, PhD, DABCC, FACB

References

 

1. Nichols JH, Bartholomew C, Bonzagi A, GarbJL, Jin L. Evaluation of the IRMA TRUpoint and i-STAT creatinine assays. Clin Chim Acta 2007;377(1-2):201-5.

 

2. Aumatell A, Sharpe D, Reed W. Validation of the StatSensor meter for testing blood before contrast computed tomography studies.  Point of Care 2010;9(1):25-31.

 

3. Skurup A, Kristensen T, Wennecke F. New creatinine sensor for point-of-care testing of creatinine meets the National Kidney Disease Education Program Guidelines. Clin Chem Lab Med 2008;46(1):3-8.

 

4. National Kidney Disease Education Program (NKDEP). Creatinine Standardization Recommendations.

March 20112011James H. Nichols, PhD, DABCC, FACBJames H. Nichols, PhD, DABCC, FACB4Approved
  
No presence informationAACC\bgarman3/15/2011 8:06 AMRenal/GI/Hepatic; Special Populations Stanley F. Lo, PhD, DABCC, FACB

IFCC Intl Congress Pediatrics May 13-15, 2011 Berlin, Germany

 

Lo SF: The Lab's Role in Diagnosis of Neonatal Hyperbilirubinemia. CLN 2010; 36.

 

Additional Reading

 

Lo SF, Jendrzejczak B, Doumas BT.  Bovine serum-based bilirubin calibrators are inappropriate for some diazo methods.  Clin Chem 2010;56:869-872.

 

American Academy of Pediatrics, Subcommittee on Hyperbilirubinemia.  Clinical practice guideline: Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.  Pediatrics  2004;114:297-316.

 

Canadian Paediatric Society, Fetus and newborn Committee.  Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks’ gestation).  Paediatr Child Health 2007;12 (5):1B-12B.

 

Karon BS, Wickremasinghe AC,  Lo SF,  Saenger AK,  Cook WJ.  BiliChek transcutaneous bilirubin meter overestimates serum bilirubin as measured by the Doumas reference method.  Clin Biochem 2010;43:1009-1012.

March 20112011Stanley F. Lo, PhD, DABCC, FACBStanley F. Lo, PhD, DABCC, FACB4Approved
  
No presence informationAACC\bgarman3/8/2011 8:05 AMTDM/Toxicology Donald L. Frederick, PhD, DABFT, FACB

Contemporary Issues in Clinical TDM/Tox

April 29, Chicago, IL

click here

 

Clinical and Forensic Toxicology News

Click here

 

Therapeutic Drug Management and Toxicology Division

Click here

 

Society of Toxicology 50th Anniversary Meeting/Expo

March 6-10, 2011, Washington, DC


References
Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: temporary placement of five synthetic cannabinoids into schedule I.  Fed Regist 2010;75:71635-8.

European Monitoring Centre for Drug and Drug Addiction. www.emcdda.europa.eu (Accessed Jan 21, 2011).

Atwood BK, Huffman J, Straiker A, Mackie K. JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Brit J Pharmacol 2010;160: 585–93.

Davies S, Wood DM, Smith G, Button J, Ramsey J, Archer R, et al. Purchasing 'legal highs' on the Internet--is there consistency in what you get? QJM 2010;103:489–93.

March 20112011Donald L. Frederick, PhD, DABFT, FACBDonald L. Frederick, PhD, DABFT, FACB2Approved
  
No presence informationAACC\bgarman3/1/2011 8:26 AMManagement/Medical Informatics Jim Faix, MD
References
 
Outdated Lab Tests
 
Requiem for a Heavy Weight
March 20112011Jim Faix, MD Jim Faix, MD39Approved
  
No presence informationAACC\bgarman2/22/2011 8:08 AMGovernment Affairs/Patient Safety; Management/Medical Informatics Corinne Fantz, PhD, DABCC, FACB

Additional Resources

Mountain PJ, Callaghan JV, Chou D, Davis RR, Hawker CD, Knafel AJ, et al. Laboratory automation: bar codes for specimen container identification; approved standard. 2nd ed. CLSI document AUTO2-A2. Vol. 25. Wayne (PA): CLSI; 2005.

 

Palmer RC. The bar code book: reading, printing, and specification of bar code symbols. 2nd ed. Peterborough, NH, Helmers Publishing; 1991.

 

Hawker CD. Bar codes may have poorer error rates than commonly believed. Clin Chem. 2010 Oct;56(10):1513-4.

 

References

1. Snyder ML, Carter A, Jenkins K, Fantz CR.  Patient Mis-identifications caused by errors in standard bar code technology.  Clin Chem. 2010 Oct;56(10):1554-60. Epub 2010 Aug 11.

 

2. Ansari S, Szallasi A. “Wrong blood in tube”” solutions for a persistent problem. Vox Sang. 2010 Aug 25. [Epub ahead of print]

 

3. Sotto LS. An RFID code of conduct. RFID Journal 2005.

 

February 20112011Corinne Fantz, PhD, DABCC, FACBCorinne Fantz, PhD, DABCC, FACB2Approved
  
No presence informationAACC\bgarman2/15/2011 10:08 AMDiabetes/Endocrinology; Instrumentation/Technology Roger Bertholf, PhD, DABCC, FACB

Additional Resources

 

Tzamaloukas AH, Ing TS, Siamopoulos KC, Rohrsheib M, Elisaf MS, Raj DSC, Murata GH. Body fluid abnormalities in severe hyperglycemia in patients on chronic dialysis: review of published reports. Journal of Diabetes and Its Complications 2008;22:29-37.

 

Katz MA. Hyperglycemia-induced hyponatremia: Calculation of the expected serum sodium depression. New England Journal of Medicine 1973;289:843-4.

 

Robin AP, Ing TS, Lancaster GA, Soung LS, Sparagana M, Geis WP, Hano JE. Hyperglycemia-induced hyponatremia: a fresh look. Clinical Chemistry 1979;25(3):496-7.

 

Elisaf M, Papagalanis ND, Siamopoulos KC. The importance of serum sodium in the symptomatology of hyperglycemic-induced hypertonicity. Journal of Nephrology 1993; 6:202-5.

 

Diabetes and Laboratory Medicine

 

Special Issue of Clinical Chemistry on Diabetes

February 20112011Roger Bertholf, PhD, DABCC, FACBRoger Bertholf, PhD, DABCC, FACB5Approved
  
No presence informationAACC\bgarman2/8/2011 8:39 AMDiabetes/Endocrinology; Instrumentation/Technology; POC Testing Stephen Kahn, PhD, DABCC, FACB
Arnold O. Beckman Conference
 
http://www.aacc.org/events/online_progs/certificates/diabetes/pages/default.aspx
Diabetes Certificate Program
February 20112011Stephen Kahn, PhD, DABCC, FACBStephen Kahn, PhD, DABCC, FACB3Approved
  
No presence informationAACC\bgarman2/1/2011 8:58 AMDiabetes/Endocrinology; Management/Medical Informatics William E. Winter, MD, FACBThe New ADA Guidelines: Using HbA1c in Diabetes Screening and DiagnosisRecent CLN HbA1c article
Special Issue on Diabetes
 
 
Diabetes Certificate Program
Diabetes Certificate Program
 
 
29th Annual Arnold O. Beckman Conference
February 20112011William E. Winter, MD, FACBWilliam E. Winter, MD, FACB7Approved
  
No presence informationAACC\bgarman1/25/2011 8:15 AMManagement/Medical Informatics; Immunology/Infectious Disease  Callum Fraser, PhDBiological Variation: From Principles to Practice
 
January 20112011Callum Fraser, PhDCallum Fraser5Approved
  
No presence informationAACC\bgarman1/18/2011 9:20 AMManagement/Medical Informatics; Molecular Pathology and Genetics Patti Jones, PhD, FACB, and Jason Park, MDThe Send-Out Testing BoomMolecular Diagnostic Testing Presents $5 Billion ConundrumAn Analysis of Reference Laboratory Testing in a Large Urban Academic Medical CenterReeling in Expense of Reference Lab Testing
January 20112011Patti Jones, PhD, FACB, and Jason Park, MDPatti Jones, PhD, FACB, and Jason Park, MD6Approved
  
No presence informationAACC\bgarman1/11/2011 9:14 AMCVD/Markers/Risk Factors; New/Other Disease Markers  Allan S. Jaffe, MD, FACBCardiac IschemiaNACB LMPG Biomarkers of Acute Coronary Syndromes and Heart Failurehs – Troponin: Can It Play a Role in Risk-Stratifying and Managing Heart Failure Patients?
Related Event
 
Additional Resource

deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010;304(22):2494-502.

January 20112011Allan S. Jaffe, MD, FACBAllan S. Jaffe, MD, FACB5Approved
  
No presence informationAACC\bgarman1/4/2011 8:01 AMInstrumentation/Technology; Special Populations; New/Other Disease Markers  David G. Grenache, PhD, FACBNACB Laboratory Medicine Practice Guidelines Maternal Fetal RiskFantz C, Grenache D, Gronowski A: The Future of Fetal Lung Maturity Testing (CD-ROM)New Paradigms in Fetal Lung Maturity TestingDr Grenache and Dr Gronowski's Blog: The Pregnancy Lab

Additional Resources

 

Haymond S, Luzzi VI, Parvin CA, et al.  A direct comparison between Lamellar body counts and the fluorescent polarization methods for predicting respiratory distress syndrome.  Am J Clin Path 2006;126:894-899

 

Lockwood CM, Crompton JC, Riley JK, et al. Validation of lamellar body counts (LBC) using three hematology analyzers. Am J Clin Path. 2010;134:420-8

 

Pineda V, Gronowski AM. Biomarkers for fetal lung maturity. Biomarkers in Medicine

 

Szallasi A, Gronowski AM, Eby CS.  Lamellar body count in amniotic fluid: a comparative study using four different hematology analyzers.  Clin Chem 2003;49:994-997

January 20112011David G. Grenache, PhD, FACBDavid G. Grenache, PhD, FACB11Approved
  
No presence informationAACC\bgarman1/4/2011 8:00 AM Patti Jones, PhD, FACB
 
 

​

January 20112011Patti Jones, PhD, FACBPatti Jones, PhD, FACB0Approved